Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CGRP

- PMLiVE

Amgen cholesterol antibody shines in rare disease trial

Evolocumab passes late-stage study

- PMLiVE

Pharma’s winners and losers in 2013

Roche, Johnson & Johnson and Amgen rise up the PMLiVE Top Pharma List rankings

- PMLiVE

Pfizer still number one – just

The PMLiVE Top Pharma List is updated with a ranking of the 25 biggest companies in the industry

- PMLiVE

New data puts Jakafi on course for blockbuster status

Novartis/Incyte drug meets targets in blood cancer trial

Novartis building

Novartis’ dermatology plans advance with Xolair approval

Green light for use in chronic spontaneous urticaria

- PMLiVE

Novartis to close UK R&D site

Research operations at Horsham expected to end in June

Novartis day

Novartis commits to greater transparency on trials

Will provide anonymised patient-level data but only for new studies

Novartis day

Novartis under fire in Japan over Diovan promotion

Offices raided amid investigation into falsified data

Novartis building

Novartis skin cancer drug clears pivotal trial

Sonidegib achieves significant response in basal cell carcinoma patients

Novartis building

Novartis enters PD-1 race via CoStim acquisition

Expands presence in cancer immunotherapies

- PMLiVE

Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte

Sees combination potential for cancer prospect

Novartis building

Novartis planning thousands more job cuts, says paper

NZZ am Sonntag claims pharma company plans to transfer roles to India

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links